2024
Analysis of drug–drug interactions in patients with HIV and metabolic syndrome
Tuan J, Igiraneza G, Ogbuagu O. Analysis of drug–drug interactions in patients with HIV and metabolic syndrome. Expert Opinion On Drug Metabolism & Toxicology 2024, 20: 953-965. PMID: 39230187, DOI: 10.1080/17425255.2024.2401044.Peer-Reviewed Original ResearchDrug-drug interactionsAntiretroviral therapyMetabolic disordersMetabolic syndromeNanotechnology-based drug delivery platformsPrevalence of metabolic comorbiditiesSelection of antiretroviral therapyLong-acting antiretroviral therapyContemporary antiretroviral therapyEffective antiretroviral therapyPrevalence of metabolic disordersRepertoire of treatment optionsDrug-drug interaction dataTreat metabolic syndromeMetabolic comorbiditiesTreatment optionsDrug delivery platformPrescribing informationAnalysis of drug-drug interactionsHIVInjectable medicationsDrug prescribing informationWeight lossPWHSyndrome
2022
Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report)
Adeiza M, Kekulah I, Wachekwa I, Ogbuagu O. Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report). PAMJ Clinical Medicine 2022, 8 DOI: 10.11604/pamj-cm.2022.8.47.33930.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAdverse drug reactionsDrug reactionsHIV programsResource-limited settingsAntiretroviral therapyHypersensitivity reactionsAdvanced HIV diseaseLamivudine/tenofovirLamivudine/zidovudineRoutine laboratory monitoringCombination antiretroviral therapyAntiretroviral drug treatmentFirst-line cARTFeatures of anaphylaxisRelevant health educationDrug discontinuityViral suppressionHIV diseaseHIV infectionBlood workOpportunistic infectionsLaboratory monitoringNew symptomsDrug treatmentMedical treatment
2021
Gaps and Opportunities in HIV Service Delivery in High Volume HIV Care Centers in Liberia: Lessons From the Field
Adeiza MA, Wachekwa I, Nuta C, Donato S, Koomson F, Whitney J, Plyler C, Kerr L, Sackey G, Dunbar E, Talbert-Slagle K, Klar R, Marsh RH, Caldwell S, Toomey J, Ogbuagu O. Gaps and Opportunities in HIV Service Delivery in High Volume HIV Care Centers in Liberia: Lessons From the Field. Annals Of Global Health 2021, 87: 115. PMID: 34900615, PMCID: PMC8622325, DOI: 10.5334/aogh.3246.Commentaries, Editorials and LettersConceptsHIV service deliveryAntiretroviral therapyOverall health system strengtheningHuman immunodeficiency virus (HIV) infectionHealth systemNon-physician healthcare workersCascade of careCombination prevention approachesHIV care centersViral load suppressionImmunodeficiency virus infectionEbola virus disease outbreakNew HIV infectionsQuality of lifePublic health impactHealth system strengtheningVirus disease outbreakResponsive health systemART initiationHIV workforceUndiagnosed HIVViral suppressionUNAIDS targetsUniversal health coverageHIV infection
2018
Dolutegravir/rilpivirine for the treatment of HIV-1 infection
Dowers E, Zamora F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. HIV/AIDS - Research And Palliative Care 2018, 10: 215-224. PMID: 30464642, PMCID: PMC6220428, DOI: 10.2147/hiv.s157855.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHIV-1 infectionDolutegravir/rilpivirineAntiretroviral therapyImportant drug-drug interactionsClinical trial efficacyDrug-drug interactionsImproved safety profileLong-term toxicityDrug package insertsRegimen simplificationMaintenance therapyCombination regimensMedication adherenceSafety profileSafety dataTrial efficacyConference abstractsPackage insertsDrug AdministrationUS FoodPharmacokinetic propertiesGoogle ScholarInfectionLimited dataRilpivirineIntegrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting
Jacobson K, Ogbuagu O. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting. Medicine 2018, 97: e13016. PMID: 30412140, PMCID: PMC6221636, DOI: 10.1097/md.0000000000013016.Peer-Reviewed Original ResearchConceptsVirologic suppressionInhibitor-based regimensAntiretroviral therapyMedian timeIntegrase strand transfer inhibitor (INSTI) classHuman immunodeficiency virus-infected patientsIntegrase inhibitor-based regimensMedian baseline CD4 countHuman immunodeficiency virus (HIV) patientsRetrospective single-center studyClinical settingProtease inhibitorsReal-world clinical settingART regimen typeVirologic suppression ratesBaseline CD4 countSingle-center studyVirus-infected patientsCells/μLCopies/mLStudy inclusion criteriaNon-nucleoside reverseRoutine clinical settingLower median timeART initiationInfections in HIV-Infected Patients
Ogbuagu O, Bruce R. Infections in HIV-Infected Patients. 2018, 243-281. DOI: 10.1007/978-3-319-77674-3_13.ChaptersHuman immunodeficiency virusCombination antiretroviral therapyCD4 countCertain infectionsLife-threatening infectious complicationsHigher CD4 countsAntiretroviral therapyImmune reconstitutionInfectious complicationsUntreated patientsImmune defectsClinical presentationImmunodeficiency syndromeCommon infectionsImmunodeficiency virusPatientsNatural historyInfectionChief causeCountCD4ComplicationsSequelaePrognosisPathogenesis
2017
Comparison of Time to Viral Suppression Among Treatment-Naïve HIV-Infected Adults Initiating Combination Antiretroviral Therapy by Antiretroviral Regimen Class
Jacobson K, Ogbuagu O. Comparison of Time to Viral Suppression Among Treatment-Naïve HIV-Infected Adults Initiating Combination Antiretroviral Therapy by Antiretroviral Regimen Class. Open Forum Infectious Diseases 2017, 4: s432-s432. PMCID: PMC5630773, DOI: 10.1093/ofid/ofx163.1090.Peer-Reviewed Original ResearchViral suppressionAntiretroviral therapyART initiationMedian timeART regimensHIV patientsRetrospective single-center chart reviewTreatment-naïve HIV patientsSingle-center chart reviewProtease inhibitorsART regimen typeTreatment-naïve HIVCombination antiretroviral therapyBaseline viral loadTreatment of HIVStudy inclusion criteriaNon-nucleoside reverseRoutine clinical settingLower median timeART regimenINSTI regimensNonstandard regimensRegimen typeVirologic suppressionVirologic failureCondomless sex and HIV transmission among serodifferent couples: current evidence and recommendations
Koff A, Goldberg C, Ogbuagu O. Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations. Annals Of Medicine 2017, 49: 534-544. PMID: 28409656, DOI: 10.1080/07853890.2017.1320423.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHIV transmissionSerodifferent couplesAntiretroviral therapyCondomless sexCondom useHIV-positive sexual partnerHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionPre-exposure prophylaxisHIV transmission riskUse of condomsInfected partnerHIV infectionHIV incidenceSexual transmissionHIV preventionPreventive benefitsVirus infectionCurrent evidencePrevention strategiesSexual partnersTransmission riskIndividual riskSexInfectionEfficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
Ogbuagu O, Hao R, Virata M, Villanueva M, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2017, 6: 620. DOI: 10.12688/f1000research.11397.1.Peer-Reviewed Original ResearchHCV genotype 1 infectionGenotype 1 infectionHCV viral loadSOF/LDVViral loadSVR 12Treatment regimenGenotype 1Sustained virologic response 12 weeksYale New Haven Health SystemIU/HCV co-infected patientsVirologic response 12 weeksCo-infected patientsHCV treatment regimenMono-infected patientsSimilar viral loadsCompletion of therapyHCV genotype 1HIV viral loadSame treatment regimenSofosbuvir/ledipasvirStudy eligibility criteriaAntiretroviral therapyHCV infection
2016
Steroid-exacerbated HIV-associated cutaneous Kaposi’s sarcoma immune reconstitution inflammatory syndrome: ‘Where a good intention turns bad’
Chabria S, Barakat L, Ogbuagu O. Steroid-exacerbated HIV-associated cutaneous Kaposi’s sarcoma immune reconstitution inflammatory syndrome: ‘Where a good intention turns bad’. International Journal Of STD & AIDS 2016, 27: 1026-1029. PMID: 26769754, DOI: 10.1177/0956462415627735.Peer-Reviewed Case Reports and Technical NotesConceptsImmune reconstitution inflammatory syndromeReconstitution inflammatory syndromeKS-IRISInflammatory syndromeKaposi's sarcomaKS lesionsSkin lesionsKaposi's sarcoma immune reconstitution inflammatory syndromeFull virologic suppressionNeck skin lesionsParadoxical worseningVirologic suppressionAntiretroviral therapyInitial presentationImmunodeficiency syndromeSteroid useClinician awarenessFacial lesionsLesionsSyndromeSarcomaGlucocorticoidsSteroidsCase discussionChemotherapy